Collegium Pharmaceutical (COLL) Lowered to “Sell” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a sell rating in a research note issued to investors on Friday.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

COLL has been the subject of several other research reports. BidaskClub cut shares of Collegium Pharmaceutical from a sell rating to a strong sell rating in a research report on Tuesday, September 18th. Cantor Fitzgerald reiterated a buy rating and issued a $35.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday. HC Wainwright reiterated a buy rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Finally, Janney Montgomery Scott set a $27.00 price objective on shares of Collegium Pharmaceutical and gave the company a buy rating in a report on Monday, August 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $31.71.

NASDAQ COLL traded down $0.14 on Friday, hitting $15.42. The stock had a trading volume of 1,701,622 shares, compared to its average volume of 338,921. Collegium Pharmaceutical has a one year low of $12.49 and a one year high of $29.90. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94. The stock has a market cap of $514.27 million, a price-to-earnings ratio of -6.24 and a beta of 0.24.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The firm had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. During the same quarter last year, the company posted ($0.45) EPS. Collegium Pharmaceutical’s revenue for the quarter was up 485.0% on a year-over-year basis. As a group, equities research analysts expect that Collegium Pharmaceutical will post -1.53 earnings per share for the current fiscal year.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $16.53, for a total value of $413,250.00. Following the completion of the transaction, the director now directly owns 361,000 shares in the company, valued at $5,967,330. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 25.76% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in Collegium Pharmaceutical by 8.1% during the third quarter. Janus Henderson Group PLC now owns 4,119,823 shares of the specialty pharmaceutical company’s stock worth $60,726,000 after buying an additional 309,477 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Collegium Pharmaceutical by 9.9% during the second quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock worth $61,732,000 after buying an additional 233,598 shares in the last quarter. BlackRock Inc. boosted its holdings in Collegium Pharmaceutical by 7.0% during the third quarter. BlackRock Inc. now owns 2,409,573 shares of the specialty pharmaceutical company’s stock worth $35,517,000 after buying an additional 157,300 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Collegium Pharmaceutical by 54.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 649,624 shares of the specialty pharmaceutical company’s stock worth $9,575,000 after buying an additional 229,968 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in Collegium Pharmaceutical by 29.7% during the third quarter. Rice Hall James & Associates LLC now owns 565,942 shares of the specialty pharmaceutical company’s stock worth $8,342,000 after buying an additional 129,432 shares in the last quarter. Hedge funds and other institutional investors own 94.41% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Recommended Story: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.